In line with this hypothesis, the immune-phenotyping of peripheral blood cells from MS patients has confirmed that DMF treatment favors CD4+ T cell polarization toward a Th2 profile and results in the reduction of Th1/Th17 cells [14]. This evidence concerns the gene CD4 and myeloid sarcoma.